文献速递生殖医学

促卵泡激素δ用于体外受精的卵巢刺激:与传统剂量促卵泡激素α比较的多中心、随机、评估者盲法试验(ADAPT-1试验)

Ovarian stimulation with follitropin delta for in vitro fertilization: a multicentre, randomized, assessor-blind comparison with follitropin alfa using conventional dosing regimens (ADAPT-1 trial).
PubMed 文献 · Hum Reprod · 2025-01-01

ADAPT-1试验将300例接受IVF/ICSI卵巢刺激的女性随机分配至促卵泡激素δ 15 µg/天(n=200)或促卵泡激素α 225 IU/天(n=100),两组获卵数均值均为9.9枚(估计差值0.0;95%CI -1.3, 1.2),临床妊娠率分别为31.6%和31.0%,早期OHSS发生率分别为2.5%和3.0%。

要点

  • 促卵泡激素δ 15 µg/天与促卵泡激素α 225 IU/天获卵数相似,估计差值为0.0枚(95%CI -1.3, 1.2)。
  • 临床妊娠率两组相当(31.6% vs 31.0%;估计差值0.6,95%CI -10.6, 11.8)。
  • 早期OHSS发生率低(2.5% vs 3.0%),所有病例为3级(中度)或以下。

核心结论

  • 促卵泡激素δ 15 µg/天与促卵泡激素α 225 IU/天起始剂量在传统 dosing 方案下卵巢反应相似,支持两者等效,且早期OHSS发生率低。

研究设计与样本

  • ADAPT-1为随机、评估者盲法、多中心试验,比较促卵泡激素δ 15 µg/天与促卵泡激素α 225 IU/天起始剂量在传统 dosing 方案中的疗效与安全性。
  • 300例18-40岁接受IVF/ICSI的女性随机接受促卵泡激素δ(n=200)或促卵泡激素α(n=100),所有周期采用GnRH拮抗剂方案。
  • 主要终点为获卵数,组间均值差异采用负二项回归模型估计(治疗和血清AMH水平作为因素)。

主要发现

  • 两组获卵数均值均为9.9枚(估计差值0.0枚;95%CI -1.3, 1.2)。
  • 获卵数8-14枚是最常见的卵巢反应类别(促卵泡激素δ:45.5%;促卵泡激素α:50.0%)。
  • 临床妊娠率相当(31.6% vs 31.0%;估计差值0.6,95%CI -10.6, 11.8)。
  • 早期OHSS(触发后≤9天)发生率分别为2.5%和3.0%,所有病例为3级(中度)或以下。
  • 促卵泡激素δ平均总剂量为143.7 ± 33.6 µg,促卵泡激素α为154.3 ± 23.1 µg(2105 ± 315 IU)。

关键数值与推荐

  • 促卵泡激素δ 15 µg/天与促卵泡激素α 225 IU/天获卵数估计差值为0.0枚(95%CI -1.3, 1.2)。
  • 临床妊娠率估计差值为0.6(95%CI -10.6, 11.8)。
  • 早期OHSS发生率促卵泡激素δ组为2.5%,促卵泡激素α组为3.0%,所有病例为3级(中度)或以下。
  • 无参与者因卵巢反应过度而取消刺激周期。

临床怎么用

  • 作者认为,促卵泡激素δ 15 µg与促卵泡激素α 225 IU起始剂量等效,早期OHSS发生率低。
  • 作者认为,促卵泡激素δ以µg为单位的卵巢刺激周期可以规划和调整,利用与促卵泡激素α已建立的IU剂量等效性。

局限性

  • 仅记录了取卵后3个月内第一次新鲜或冷冻移植的妊娠,未随访首次移植后的累积妊娠率。
  • 所有分析均为描述性,未进行正式假设检验或多重性调整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: How do ovarian responses using conventional dosing for follitropin delta 15 µg/day compare with follitropin alfa 225 IU/day in women undergoing ovarian stimulation? SUMMARY ANSWER: The ADAPT-1 trial demonstrates similar ovarian responses with follitropin delta 15 µg/day and follitropin alfa 225 IU/day starting doses in a conventional dosing regimen. WHAT IS KNOWN ALREADY: Follitropin delta, a recombinant FSH (rFSH), is currently approved for ovarian stimulation using an individualized fixed daily dose based on serum anti-Müllerian hormone (AMH) and bodyweight (maximum 12 µg/day for first cycle and 24 µg/day in subsequent cycles). Other rFSHs, such as follitropin alfa, conventionally apply a starting dose of 150-225 IU, fixed for the initial days of stimulation, after which dose adjustments can be made (maximum 450 IU/day). Ovarian stimulation with follitropin delta 10 µg/day provides a similar ovarian response to follitropin alfa 150 IU/day for serum concentration and number of follicles ≥12 mm. STUDY DESIGN, SIZE, DURATION: ADAPT-1 was a randomized, accessor-blinded, multicentre trial comparing efficacy and safety of a starting dose of follitropin delta 15 µg/day with follitropin alfa 225 IU/day in conventional dosing regimens. The primary endpoint was the number of oocytes retrieved; mean difference between treatment groups was estimated using a negative binomial regression model (treatment and serum AMH level as factors). During the follow-up period, clinical pregnancies resulting from the first fresh/frozen transfers within 3 months of the start of stimulation, and ovarian hyperstimulation syndrome (OHSS) rates were assessed. PARTICIPANTS/MATERIALS, SETTING, METHODS: Participants, 18-40 years, undergoing IVF/ICSI could enrol at specialist reproductive clinics in Austria, France, Italy, Spain, and the United Kingdom for ovarian stimulation if they had no contraindications for treatment with a starting gonadotropin dose of 225 IU/day. Patients could enrol if they reported infertility for at least 1 year if ≤37 years and at least 6 months for those >37 years, and regular menstrual cycles (21-35 days). All cycles used a GnRH antagonist protocol. MAIN RESULTS AND THE ROLE OF CHANCE: Between 1 August 2022 and 16 April 2024, 300 of 337 screened patients were randomized to, and received, follitropin delta (n = 200) or follitropin alfa (n = 100). The two treatment groups were comparable in terms of demographics, baseline characteristics, and duration of infertility. The mean duration of treatment was ∼9 days in both groups. The mean total dose of follitropin delta was 143.7 ± 33.6 µg and 154.3 ± 23.1 µg (2105 ± 315 IU) for follitropin alfa. Three-quarters (226/300) used an human Chorionic Gonadotropin trigger for final follicular maturation. A mean of 9.9 oocytes was retrieved for both groups (estimated difference: 0.0 oocytes; 95% CI -1.3, 1.2). The category of 8-14 oocytes retrieved was the most common ovarian response (follitropin delta: 45.5%; follitropin alfa: 50.0%). Clinical pregnancy rates were comparable (31.6% and 31.0%; estimated difference 0.6 (95% CI -10.6, 11.8)). Early OHSS (≤9 days after triggering) occurred in 2.5% and 3.0%, and all cases were Grade 3 (moderate) or lower. No participant had the stimulation cycle cancelled due to excessive ovarian response. LIMITATIONS, REASONS FOR CAUTION: Only pregnancies from the first fresh or cryopreserved transfer within 3 months of oocyte retrieval were recorded. Cumulative pregnancy rates after the first transfer were not followed up. All analyses are of descriptive nature and no formal hypothesis testing or multiplicity adjustment was applied. WIDER IMPLICATIONS OF THE FINDINGS: Treatment groups had similar ovarian responses, supporting equivalence for starting doses follitropin delta 15 µg and follitropin alfa 225 IU, with low rates of early OHSS. Ovarian stimulation cycles with follitropin delta in µg can be planned and adjusted, leveraging the established IU dose equivalence to follitropin alfa. STUDY FUNDING/COMPETING INTEREST(S): This trial was funded by Ferring Pharmaceuticals A/S, Kastrup, Denmark. Medical writing support for manuscript development was provided by Celia J. Parkyn, PhD, and was funded by Ferring Pharmaceuticals A/S, Kastrup, Denmark. P.Z. and R.A. have none. A.B. has received grants from Gedeon Richter, IBSA, GP Pharm & Seid, Miguel Hernandez University, Centre for Technological Development and Innovation, Valencian Innovation Agency, Regional Secretary for Industry, Trade and Consumption, and the Government Ministry of Industry and Tourism; payments from University Complutense of Madrid, Ferring Pharmaceuticals, Fentypharm, Miguel Hernandez University, Gedeon Richter, & Vall d'Hebron Hospital; travel support from Ferring Pharmaceuticals, Fentypharm, Gedeon Richter, International ESHRE Congress Organising Committee, Spanish Society of Gynaecology and Obstetrics, CROG Congress Organising Committee, & Vall d'Hebron Hospital; has a patent pending for Sperm plate (U202431456); and is Chair of the Organising Committee of the Infertility and Sterility Section of the Spanish Society of Gynaecologist (non-paid role) and equipment from Obstetrics; & equipment from Cook Medical. J.S. has received consulting fees from Ferring Pharmaceuticals. E.P. has received grants from Merck, Ferring, Theramex, Gedeon Richter, IBSA, and Organon; payments from Merck, Ferring, IBSA, and Organon; travel support from Merck, IBSA, Organon, Theramex, and Ferring; and participated in a Safety Monitoring Board or Advisory Board for Merck. M.G.S. has received patient medication from Ferring; payments from Ferring, Merck for educational events; and travel support from Ferring, Merck, Theramex, and IBSA. R.L. and S.M. are employees of Ferring Pharmaceuticals. I.E.J. was an employee of Ferring Pharmaceuticals at the time of the trial conduct. TRIAL REGISTRATION NUMBER: clinicaltrials.gov NCT05263388; Eudract 2021-001785-38. TRIAL REGISTRATION DATE: 16 November 2021 (clinicaltrials.gov); 5 August 2021 (Eudract). DATE OF FIRST PATIENT’S ENROLMENT: 1 August 2022.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Bernabeu A, Zajc P, García Sánchez M, et al. Ovarian stimulation with follitropin delta for in vitro fertilization: a multicentre, randomized, assessor-blind comparison with follitropin alfa using conventional dosing regimens (ADAPT-1 trial). Hum Reprod. 2025. PMID: 40633120. doi:10.1093/humrep/deaf119

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。